NVONOVO NORDISK A S

NYSE novonordisk.com


$ 144.28 $ 0.39 (0.27 %)    

Thursday, 27-Jun-2024 13:45:29 EDT
QQQ $ 481.80 $ 1.82 (0.38 %)
DIA $ 392.17 $ 1.38 (0.35 %)
SPY $ 546.21 $ 0.72 (0.13 %)
TLT $ 93.61 $ 0.18 (0.19 %)
GLD $ 214.99 $ 0.28 (0.13 %)
$ 143.67
$ 143.89
$ 130.00 x 100
$ 144.29 x 100
$ 143.46 - $ 145.30
$ 74.66 - $ 148.15
4,356,864
na
647,952
$ 0.64
$ 0.00
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 novo-nordisk-buys-2seventys-hemophilia-a-program-divestiture-supports-exclusive-focus-on-abecma

2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editin...

 volkswagen-puts-our-rivian-bet-in-the-black-the-pros-and-cons-of-trading-options-versus-stocks

Novo Nordisk, Carvana, And Now Rivian  We've had bullish moves in three stocks we had bullish bets on this week, and since...

 novo-nordisk-to-restrict-initial-wegovy-sales-in-china-amid-high-demand

Novo Nordisk will limit initial sales of Wegovy in China to manage global supply and address the rising obesity rates in the wo...

 hims--hers-health-stock-is-sliding-thursday-whats-going-on

Hunterbrook releases a bearish report alleging that Hims & Hers sells knockoff GLP-1 weight loss drugs and relies on a sing...

Core News & Articles

https://www.bloomberg.com/news/articles/2024-06-27/novo-will-limit-wegovy-s-china-launch-to-avoid-global-disruption?utm_content...

 ben--jerrys-co-founders-not-worried-about-ozempics-impact-on-ice-cream-business-heres-why

Ben Cohen and Jerry Greenfield, the co-founders of Ben & Jerry's, are not worried about the impact of weight-loss drugs...

Core News & Articles

- Divestiture Supports Company Focus on Development and Commercialization of Abecma-

 novo-nordisk-halts-late-stage-study-of-experimental-hypertension-drug-takes-over-800m-impairment-charge

Novo Nordisk announced the failure of its phase 3 CLARION-CKD trial, which investigated ocedurenone for treating uncontrolled h...

 novo-nordisk-stops-ocedurenone-clarion-ckd-trial-and-recognizes-impairment-loss

- Reuters

 reported-earlier-novo-nordisk-stops-the-ocedurenone-clarion-ckd-trial-and-recognises-impairment-loss-clarion-ckd-phase-3-trial-failed-to-meet-its-primary-endpoint-it-will-recognize-an-impairment-loss-of-around-dkk-57-billion-related-to-intangible-asset-ocedurenone-in-q2-of-2024-corresponds-to-estimated-negative-impact-of-around-6-percentage-points-on-operating-profit-growth-at-cer-in-2024-compared-to-operating-profit-outlook-communicated-in-q1-report

- Reuters

 rivian-lucid-micron-technology-novo-nordisk-tesla-why-these-5-stocks-are-on-investors-radars-today

On Tuesday, U.S. stocks showed mixed results. The Dow Jones Industrial Average closed down by nearly 0.8%, finishing at 39,112.16

 novo-nordisks-older-generation-weight-loss-drug-saxenda-associated-with-decreased-bone-mass-density-study-shows

Novo Nordisk's Saxenda study published in JAMA Network Open reveals significant declines in bone density among patients, ra...

 bmo-capital-maintains-outperform-on-novo-nordisk-maintains-163-price-target

BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Outperform and maintains $163 price target.

 why-novo-nordisk-shares-are-trading-higher-tuesday

The company's weight loss drug Wegovy has been approved in China, the second most populated country that is estimated to ha...

 novo-drug-saxenda-increases-bone-health-risks-study-finds-researcher-says-bone-health-risks-also-apply-to-ozempic-wegovy

- Bloomberg 

 novo-nordisk-surges-nearly-3-after-weight-loss-drug-wegovy-wins-approval-in-china

Novo Nordisk's weight loss drug Wegovy has received approval in China, representing a notable achievement for the Danish ph...

 wegovy-ozempic-maker-novo-nordisk-to-invest-41b-in-us-manufacturing-doubling-plant-size-to-meet-surging-demand-for-weight-loss-drugs

Novo Nordisk A/S is set to invest $4.1 billion in expanding its U.S. manufacturing operations to meet the increasing demand for...